This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

CAMHS won't see you now

Researchers raise questions on safety of whole-cell pertussis

Demands for the Government to switch from whole-cell DTP vaccine to the acellular (DTaP) equivalent are mounting as new research raises safety concerns about whole-cell DTP in the childhood immunisation schedule.

Results from a systematic review showed that DTaP

was as effective and had a consistently better safety profile than whole-cell vaccines, irrespective of age at vaccination.

Study lead Dr Tom Jefferson, co-ordinator of the Cochrane Vaccines Field in Rome, reviewed data from nine randomised controlled trials comparing the safety and efficacy of acellular and whole-cell pertussis vaccines, both alone and combined with diphtheria and tetanus.

Dr Jefferson, who presented the results last month at the International Society of Pharmacovigilence in Amsterdam, said the three- and five-component DTaP vaccines were as 'efficacious' against milder and more severe disease as whole-cell DTP. The study also showed whole-cell DTP caused far more local swelling, low- and high-grade fever, prolonged crying and possibly convulsions than DTaP.

Dr Jefferson, who has submitted the review to the BMJ, said: 'Why are British children still being vaccinated with whole cell?'

Currently children are given one dose of whole-cell DTP at two, three and four months and a pre-school booster of three-component DTaP between three and five years.

Vaccines expert Professor Adam Finn, professor of paediatrics at the University of Bristol, said the study was 'quite convincing' and whole-cell DTP could be replaced with DTaP as early as next year.

He said: 'I think we should be using acellular pertussis in the childhood schedule. I think it causes fewer side-

effects and the study appears to show that the three- and five-component DTaP vaccines have the same effectiveness as whole-cell DTP.'

A Department of Health spokesman said they would consider switching when the five-component DTaP vaccine was licensed in the UK.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say